Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
-Parsippany, NJ – September 21, 2023 – Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection after antibiotic treatment, as part of Infectious Disease Week (IDWeek) 2023. The congress will take place in Boston, Mass., from […]
-
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
-Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the first and only FDA-approved intravesical gene therapy Ferring launches ABLE-41 Real World Evidence Study, a patient registry to explore early use, experiences and outcomes of ADSTILADRIN in a real-world setting Ferring on track to increase manufacturing supplies of new gene […]
-
Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)
-Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) Transaction provides Ferring with significant non-dilutive capital to support the manufacturing capacity expansion, commercialization and further clinical development of Adstiladrin for bladder cancer patients in the United States Saint-Prex, Switzerland […]